Astellas Sells Diabetes Drug Patents To U.S. Investor For $209 Million
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma said it is selling its patents for a line of treatments for Type 2 diabetes to a U.S. investment fund for $609 million